Dr. Jae-Ouk Kim is the Head of Molecular Immunology at the International Vaccine Institute (IVI). She graduated from the College of Pharmacy at Seoul National University (SNU) and continued her graduate studies, majoring in immunology at SNU and completing her Ph.D. She then served as a postdoctoral fellow at the Vaccine Research Center/NIAID/NIH, USA, before joining IVI in 2008. As a research scientist in the neonatal vaccine program at IVI in 2010, she led the assessment of the maternal effect on specific immune responsiveness to BCG, a number of candidate TB vaccines, and respiratory syncytial virus glycoprotein core fragment in neonatal mice. She also studied the role of neonatal NKT cell sensitization in RSV disease in mice. Currently, her research has focused on the development of a universal Shigella vaccine targeting conserved outer membrane proteins. She is also leading a project involving the development of neutralizing antibodies against hemorrhagic fever viruses, such as the Ebola virus. Besides serving as the principal investigator in various research projects, Dr. Kim led the strategic study on the establishment and management of the Reference Lab for Clinical Evaluation of
Vaccines, funded by the Korean Ministry of Food and Drug Safety. She is also involved in establishing a MERS-CoV vaccine evaluation system.
Dr. Jae-Ouk Kim is the Head of Molecular Immunology at the International Vaccine Institute (IVI). She graduated from the College of Pharmacy at Seoul National University (SNU) and continued her graduate studies, majoring in immunology at SNU and completing her Ph.D. She then served as a postdoctoral fellow at the Vaccine Research Center/NIAID/NIH, USA, before joining IVI in 2008. As a research scientist in the neonatal vaccine program at IVI in 2010, she led the assessment of the maternal effect on specific immune responsiveness to BCG, a number of candidate TB vaccines, and respiratory syncytial virus glycoprotein core fragment in neonatal mice. She also studied the role of neonatal NKT cell sensitization in RSV disease in mice. Currently, her research has focused on the development of a universal Shigella vaccine targeting conserved outer membrane proteins. She is also leading a project involving the development of neutralizing antibodies against hemorrhagic fever viruses, such as the Ebola virus. Besides serving as the principal investigator in various research projects, Dr. Kim led the strategic study on the establishment and management of the Reference Lab for Clinical Evaluation of
Vaccines, funded by the Korean Ministry of Food and Drug Safety. She is also involved in establishing a MERS-CoV vaccine evaluation system.